Keyword: Risperdal

An $8 billion jury verdict against Johnson & Johnson raised eyebrows back in October, but the judge has now slashed damages to just $6.8 million.

A Pennsylvania appeals court upheld a 2016 Risperdal verdict against Johnson & Johnson worth $70 million in actual damages.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.

Jurors smacked J&J with a massive $8 billion verdict in the case of a young man who developed breasts while taking its antipsychotic drug Risperdal.

Right before a trial, Johnson & Johnson inked a settlement to resolve allegations its antipsychotic Risperdal caused a patient to develop breasts.

At least 18 federal lawsuits claiming Johnson & Johnson’s talc-based powders caused ovarian cancer could be consolidated for pretrial work, and J&J wants that litigation in New Jersey, its home state.

Another jury smacked J&J with damages in a Risperdal breast-development case. But this time, that verdict came to $70M--far more than previous verdicts in similar cases.